The evaluation of potential pharmacokinetic interaction between sirolimus and tacrolimus in healthy volunteers

European Journal of Clinical Pharmacology

Volumn 69, Issue 4, 2013, Pages 835-842

  Tortorici, Michael A ^a   Parks, Virginia ^a,b   Matschke, Kyle ^a   Korth Bradley, Joan ^a   Patat, Alain ^a,c  

^a PFIZER INC   (United States)

^b Shire Pharmaceuticals   (France)

^c Biotrial   (France)

Author keywords

CYP450 3A4; Drug interaction; Renal transplantation; Sirolimus; Tacrolimus

Indexed keywords

RAPAMYCIN; TACROLIMUS;

ADULT; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG TOLERABILITY; DRUG TRANSPORT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; OPEN STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; VASODILATATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; BRAZIL; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; FASTING; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SIROLIMUS; TACROLIMUS; YOUNG ADULT;

EID: 84876728590     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-012-1407-2     Document Type: Article

References (29)

1. Wyeth Pharmaceuticals (2011) Rapamune package insert. Wyeth Pharmaceuticals, Philadelphia
2. Kahan BD (2000) Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. The Rapamune US Study Group. Lancet 356:194-202
3. MacDonald AS (2001) A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 71:271-280
4. Astellas Pharma (2012) Prograf package insert. Astellas Pharma US, Deerfield
5. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL (1991) Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815
6. Choi J, Chen J, Schreiber SL, Clardy J (1996) Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 273:239-242
7. Vu MD, Qi S, Xu D, Wu J, Fitzsimmons WE, Sehgal SN, Dumont L, Busque S, Daloze P, Chen H (1997) Tacrolimus (FK506) and sirolimus (rapamycin) in combination are not antagonistic but produce extended graft survival in cardiac transplantation in the rat. Transplantation 64:1853-1856
8. Morris RE, Meiser BM, Wu J, Shorthouse R, Wang J (1991) Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. Transplant Proc 23(1 pt 1):521-524
9. McAlister VC, Gao Z, Peltekian K, Domingues J, Mahalati K, MacDonald AS (2000) Sirolimus-tacrolimus combination immunosuppression. Lancet 355:376-377
10. Mahalati K, Kahan BD (2001) Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 40:573-585
11. MacDonald A, Scarola J, Burke JT, Zimmerman JJ (2000) Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus. Clin Ther 22[Suppl B]:B101-B121
12. Undre NA (2003) Pharmacokinetics of tacrolimus-based combination therapies. Nephrol Dial Transplant 18[Suppl 1]:i12-i15
13. Undre NA, Stevenson P, Schäfer A (1999) Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 31:21S-24S
14. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuckerman S, Warty V, McMichael J, Lever J, Burckart G, Starzl T (1995) Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet 29:404-430
15. Lampen A, Christians U, Guengerich FP, Watkins PB, Kolars JC, Bader A, Gonschior AK, Dralle H, Hackbarth I, Sewing KF (1995) Metabolism of the immunosuppressant tacrolimus in the small intestine: cytochrome P450, drug interactions, and interindividual variability. Drug Metab Dispos 23:1315-1324
16. Lampen A, Zhang Y, Hackbarth I, Benet LZ, Sewing KF, Christians U (1998) Metabolism and transport of the macrolide immunosuppressant sirolimus in the small intestine. J Pharmacol Exp Ther 285:1104-1112
17. Sattler M, Guengerich FP, Yun CH, Christians U, Sewing KF (1992) Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab Dispos 20:753-761
18. Crowe A, Lemaire M (1998) In vitro and in situ absorption of SDZ-RAD using a human intestinal cell line (Caco-2) and a single pass perfusion model in rats: comparison with rapamycin. Pharm Res 15:1666-1672
19. Masuda S, Uemoto S, Hashida T, Inomata Y, Tanaka K, Inui K (2000) Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient. Clin Pharmacol Ther 68:98-103
20. Zimmerman JJ, Harper D, Getsy J, Jusko WJ (2003) Pharmacokinetic interactions between sirolimus and microemulsion cyclosporine when orally administered jointly and 4 hours apart in healthy volunteers. J Clin Pharmacol 43:1168-1176
21. Squifflet JP, Vanrenterghem Y, van Hooff JP, Salmela K, Rigotti P, for the European Tacrolimus/MMF Transplantation Study Group (2002) Safe withdrawal of corticosteroids or mycophenolate mofetil: results of a large, prospective, multicenter, randomized study. Transplant Proc 34:1584-1586
22. Van Duijnhoven EM, Boots JM, Christiaans MH, Stolk LM, Undre NA, van Hooff JP (2003) Increase in tacrolimus trough levels after steroid withdrawal. Transpl Int 16:721-725
23. Park SI, Felipe CR, Pinheiro-Machado PG, Garcia R, Fernandes FB, Casarini DE, Tedesco-Silva H Jr, Medina-Pestana JO (2009) Tacrolimus pharmacokinetic drug interactions: effect of prednisone, mycophenolic acid or sirolimus. Fundam Clin Pharmacol 23:137-145
24. McAlister VC, Mahalati K, Peltekian KM, Fraser A, MacDonald AS (2002) A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration. Ther Drug Monit 24:346-350
25. Kahan BD, Napoli KL, Kelly PA, Podbielski J, Hussein I, Urbauer DL, Katz SH, Van Buren CT (2000) Therapeutic drug monitoring of sirolimus: correlations with efficacy and toxicity. Clin Transplant 14:97-109
26. Baldan N, Rigotti P, Furian L, Margani G, Ekser B, Frison L, De Martin S, Palatini P (2006) Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients. Pharmacol Res 54:181-185
27. Pfizer (2012) Data on file. Pfizer Inc, Collegeville, PA
28. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-653
29. Jones K, Saadat-Lajevardi S, Lee T, Horwatt R, Hicks D, Johnston A, Holt DW (2000) An immunoassay for the measurement of sirolimus. Clin Ther 22[Suppl 2]:B49-B61